LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma : Implications for therapeutic drug monitoring
No Thumbnail Available
Date
2021-11-15
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The pharmacokinetic profiling of drug substances and corresponding metabolites in the biological matrix is one of the most informative tools for the treatment efficacy assessment. Therefore, to satisfy the need for comprehensive monitoring of anti-tuberculosis drugs in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantification of first-line anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide, and rifampicin) along with their six primary metabolites. Simple single-step protein precipitation with methanol was chosen as the most convenient sample pre-treatment method. Chromatographic separation of the ten analyte mixture was achieved within 10 minutes on a reverse-phase C8 column using mobile phase gradient mode. The multiple reaction monitoring mode (MRM) was used for analyte detection and quantification in patient samples. The chosen quantification ranges fully covered expected plasma concentrations. The method exhibited acceptable selectivity; the within- and between-run accuracy ranged from 87.2 to 113.6%, but within- and between-run precision was between 1.6 and 14.9% (at the LLOQ level CV < 20%). Although the response of the isonicotinic acid varied depending on the matrix source (CV 21.8%), validation results proved that such inconsistency does not affect the accuracy and precision of results. If stored at room temperature plasma samples should be processed within 4 h after collection, temporary storage at −20 °C up to 24 h is acceptable due to stability issues of analytes. The developed method was applied for the patient sample analysis (n = 34) receiving anti-tuberculosis treatment with the first-line drugs.
Description
Funding Information: This study was funded by the Latvian Council of Science. Project No: lzp-2020/1-0050. Publisher Copyright: © 2021 The Authors
Keywords
LC-MS/MS, Pharmacokinetics, Therapeutic drug monitoring, Tuberculosis, 1.4 Chemical sciences, 3.1 Basic medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, Analytical Chemistry, Biochemistry, Clinical Biochemistry, Cell Biology, SDG 3 - Good Health and Well-being
Citation
Kivrane, A, Grinberga, S, Sevostjanovs, E, Igumnova, V, Pole, I, Viksna, A, Bandere, D, Krams, A, Cirule, A, Pugovics, O & Ranka, R 2021, 'LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma : Implications for therapeutic drug monitoring', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1185, 122986. https://doi.org/10.1016/j.jchromb.2021.122986